4 Healthcare Stock Stories Making Sector Headlines Thursday
Celgene Corp. (NASDAQ:CELG): Closing price $145.59
Celgene Corp.’s wholly-owned subsidiary Celgene International Sàrl, announced Thursday that updated results from MM-003, a phase III multi-center, randomized open-label study of pomalidomide (marketed as POMALYST in the United States and IMNOVID in the European Union) plus low-dose dexamethasone, were published online prior to print in The Lancet Oncology. The evaluation compared oral pomalidomide plus low-dose dexamethasone with high-dose dexamethasone in patients suffering from refractory or relapsed and refractory multiple myeloma, who have failed a minimum of two prior therapies with both bortezomib and lenalidomide, administered alone or in combination.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.